Present topline data from KOMET-001 Phase 2 trial in R/R NPM1-m AML
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Feb 2025
- Due
- 30 Jun 2025
- Delivered
- 2 Jun 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Present topline data from KOMET-001 Phase 2 registration-directed trial in R/R NPM1-m AML 2Q 2025”
What we found
Evidence strength B What the grades mean
Kura and Kyowa Kirin presented KOMET-001 topline data in an oral presentation at the 2025 ASCO Annual Meeting, with an associated investor event on June 2, 2025, meeting the 2Q 2025 deadline.
-
B Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting Confirms ASCO oral presentation and June 2, 2025 investor event on KOMET-001 data
-
B Kura Oncology Reports First Quarter 2025 Financial Results States KOMET-001 topline data accepted for oral presentation at ASCO and EHA
-
C Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results States the original 2Q 2025 milestone commitment for presenting KOMET-001 topline data
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Kura Oncology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-KURA-000247 · Corrections policy